These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 27558232)

  • 1. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
    Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
    J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
    Salem AH; Agarwal SK; Dunbar M; Nuthalapati S; Chien D; Freise KJ; Wong SL
    J Clin Pharmacol; 2016 Nov; 56(11):1355-1361. PubMed ID: 27029823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
    Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
    AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
    Salem AH; Dunbar M; Agarwal SK
    Anticancer Drugs; 2017 Sep; 28(8):911-914. PubMed ID: 28562380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
    Cheung TT; Salem AH; Menon RM; Munasinghe WP; Bueno OF; Agarwal SK
    Clin Pharmacol Drug Dev; 2018 May; 7(4):435-440. PubMed ID: 29058801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
    Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
    Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
    Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
    J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
    Minocha M; Zeng J; Medema JK; Othman AA
    Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.